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epatitis C virus (HCV) 
and HIV infection are 
both major global health 
problems, each with their own 
speciﬁc unsolved and difﬁcult 
issues of prevention, pathogenesis, 
and therapy. For HIV, many of the 
clinical problems experienced are 
related to loss of immunological 
control over relatively commonly 
encountered pathogens. In most of 
these cases (e.g., cytomegalovirus 
[CMV], Pneumocystis jiroveci, human 
herpesvirus-8), normal immunological 
control is quite efﬁcient, and these 
organisms behave as “opportunists.” 
HCV is slightly different, in that 
immunological control in normal 
HIV-uninfected individuals is often 
poor, and HCV infection alone can 
lead to the gradual evolution of end-
stage liver disease in normal hosts. 
However, although a consensus is 
forming about the basic details of the 
immune responses associated with 
acute control of HCV monoinfection, 
the long-term relationships between 
immune responses, viral load, and most 
importantly, disease progression in 
those who are persistently infected are 
still poorly understood.
HIV–HCV coinfection is a problem 
of substantial size. Overall the ﬁgures 
for coinfection rates are very striking—
around one in 10 of those infected with 
HIV globally are also HCV infected 
(around 4–5 million) [1]. In the West, 
however, the infection rate is one in 
four, and in speciﬁc risk groups, such 
as intravenous drug users, the ﬁgure 
rises to up to 50%–95%, regardless of 
global location. This reﬂects the fact 
that HCV is relatively easy to spread 
through percutaneous infection, while 
relatively harder to spread through 
sexual contact.
The coinfection rate would matter 
little on its own if the consequences 
were not so grave. HIV infection has a 
major effect on HCV viral load [2] and 
a clinically signiﬁcant effect on HCV 
disease progression [3]. Furthermore, 
although effective antiretroviral therapy 
(ART) has transformed the course of 
HIV disease progression, HCV-related 
liver disease is still a signiﬁcant cause of 
morbidity and mortality in this group 
[4].
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Figure 1. Immunologic Control of HCV Pathogenesis
In a normal HCV monoinfection, HCV-speciﬁc CD4 and CD8 T cells are mobilized to contain 
infection. If infection is not cleared, such T cells contribute to antiviral effects, proinﬂammatory 
effects, and regulatory effects. There is emerging evidence that the high viral loads of HCV during 
coinfection with HIV are associated with profound defects in HCV-speciﬁc CD4 and also CD8 T 
cell responses. There are some data showing that the cytokine environment in the liver is altered, 
which could affect disease progression independently from any inﬂuence of virus load.
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In this Research in Translation article, 
we discuss our current understanding of 
the immunopathogenesis of HCV–HIV 
coinfection. We ﬁrstly discuss what is 
known of the host immune response in 
HCV monoinfection, and subsequently 
the impact of HIV on this response. 
We focus on two issues—immune 
deﬁciency and immune dysregulation, 
which we propose combine to produce 
the clinical picture associated with 
coinfection.
Immune Responses during HCV 
Infection
Resolving infection. HCV sets up long-
term persistence in the majority of 
those infected—around 75% overall 
[5]. In individual cohorts, however, 
the spontaneous clearance rate may 
be somewhat higher, up to 50% [6]. 
The mechanisms that contribute to 
spontaneous clearance include innate 
and adaptive immunity. At the time 
of acute infection, there is evidence 
for the generation of strong T cell 
responses, both CD4+ and CD8+, which 
are temporally associated with control 
of viremia [7,8]. Furthermore, in 
animal model experiments, removal 
of these subsets leads to failure to 
control viremia [9,10]. At the genetic 
level, in human infection there is 
the linkage between speciﬁc human 
leukocyte antigen (HLA) class I and 
class II molecules (e.g., HLA-B27 [6] 
and HLA-DR11 [11]) with clearance of 
virus, indicating that the presentation 
of speciﬁc viral peptides through 
molecules leads to protective responses. 
Data illuminating the immunologic 
basis of these genetic associations with 
disease outcome are emerging [12].
Although antibody responses are 
mounted, these are somewhat delayed, 
and limited by the rapid emergence 
of escape mutants (see below). The 
emerging consensus is that strong T 
cell responses accompanied by innate 
mediators dominate to control infection 
successfully. If virus is contained in 
this acute phase, strong memory T cell 
responses are detectable in the long 
term, although antibody responses may 
wane relatively quickly [13].
Persistent infection. In those who 
become persistently infected, the 
virus must evade host innate and 
adaptive immunity. The fundamental 
differences between the initial 
responses that are successful in 
containing virus, compared to those 
that are unsuccessful, have been 
difﬁcult to pinpoint. Most individuals 
do mount measurable CD4+ and CD8+
T cell responses in the acute phase, 
but if virus persists, these responses 
are generally not sustained at high 
levels [8,14]. Many responses become 
undetectable by conventional assays, or 
are present at very low levels in blood. 
Those that are detectable have been 
described as weak in speciﬁc functions, 
notably proliferative capacity [15]. 
This picture contrasts strongly with 
other persistent virus infections such as 
CMV or HIV, although similar loss of 
reactivity is seen in chronic hepatitis B 
infection [16].
Evasion of host adaptive immunity 
by HCV and downregulation of T 
cell responses may occur through a 
number of mechanisms. Firstly, the 
high levels of viral production (greater 
than 1010 viral particles per day) and 
the variable viral genome leads to 
emergence of escape mutations. These 
are evident both in the envelope 
genes, as a consequence of antibody-
mediated selection pressure [17], 
and throughout the genome within 
speciﬁc CD8+ T cell epitopes [18,19]. 
The capacity of HCV to escape both 
antibody and T cell responses is evident 
in longitudinal studies of infected 
individuals, but also to some extent 
in cross-sectional analyses of infected 
patients, where the “footprint” of 
speciﬁc HLA-restricted T cell responses 
may be observed [19,20].
A further mechanism that may 
help HCV elude host immunity is the 
induction of T cell exhaustion. This 
phenomenon relates to the sequential 
loss of T cell functions in the presence 
of high levels of virus, followed 
ultimately by the deletion of such cells. 
The mechanisms leading to exhaustion 
are not fully clear. One line of recent 
evidence suggests that the inhibitory 
molecule programmed death-1 may be 
implicated [21]. A similar mechanism 
probably occurs in both CD4+ and CD8+
T cells and has been demonstrated in 
chronic HIV infection [22]. Exhaustion 
of CD8+ T cells is strongly inﬂuenced by 
the function of CD4+ T cells in animal 
models [23]—thus loss of CD4+ T cell 
activity profoundly affects the ability to 
sustain functional antiviral CD8+ T cell 
populations.
A ﬁnal factor that is hypothesized 
to modify the host T cell response to 
HCV is the induction of regulatory 
T cell subsets. Such cells, which are 
best tracked using the expression 
of transcription factor FOXP3, have 
been demonstrated in many chronic 
inﬂammatory states and infections, 
including HCV [24]. Regulatory T 
cells may be generated in the thymus 
(natural Tregs) or in the periphery, 
as a result of antigenic stimulation, 
and act to inhibit function of antigen-
speciﬁc T cells, including HCV-
speciﬁc CD8+T cells [25,26]. They 
may produce interleukin-10 (IL-10) 
and transforming growth factor-
beta (TGF-beta), both of which are 
inhibitory cytokines. It is generally 
considered that such T cell populations 
serve to limit immunopathology and 
autoimmunity. Further careful study 
is needed in this arena to examine the 
role of these cells in HCV infection.
Multiple studies using diverse 
techniques demonstrate that patients 
Table 1. Major Clinical Impacts of HIV on HCV and Immunologic Correlates
Key Clinical Observation Immunologic Correlates References
Increased persistence rate Reduced acute T cell responses [2,55]
Increased recurrence rate Reduced post-acute T cell responses [57,58,59]
Increased virus load Reduced steady state CD4+ and CD8+ T cell responses [2,52,53,56]
Reduced HCV treatment responses  Increased virus load (consequence of reduced T cell responses?a) [42,80,81]
Increased liver ﬁbrosis rates  Increased virus load?a Reduced regulatory responses?a [3,35,48,49,50]
For full reference list see text.
aThis theory still needs proof to support it.
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who present with chronic HCV 
infection exhibit relatively weak ex 
vivo T cell responses in blood assays 
(reviewed in [27]). It has been very 
difﬁcult to relate these responses 
closely to either the viral load or the 
degree of liver inﬂammation and/or 
hepatic ﬁbrosis. This may be due in 
part to the technical difﬁculties of 
such studies—it has generally been 
hard to deﬁne such relationships in 
HIV, which elicits much larger T cell 
responses and has been much more 
extensively investigated (reviewed in 
[16]). It is also difﬁcult to correlate 
measurements from one time point at 
liver biopsy with an outcome (ﬁbrosis) 
that often takes decades to develop. 
In addition, the enormous antigenic 
variation present in HCV makes such 
assays difﬁcult both to perform and 
interpret. Further complications 
emerge from the failure to adequately 
visualize responses in the liver, the 
main focus of the pathology, as will be 
discussed below.
Immune Responses in the Liver
A number of studies have attempted 
to analyze CD8+ and CD4+ responses 
in the liver of HCV-monoinfected 
patients. This is rarely done in 
acute disease outside animal model 
settings. When studied acutely, there 
is a substantial period where virus is 
present at high levels, but no tissue 
damage or inﬂammatory inﬁltrate is 
observed [9,10]. This is important for 
two reasons. Firstly, it suggests that 
on its own, the virus causes relatively 
little tissue damage, at least in the 
short term, and thus explains the 
lack of a robust link between viral 
load and disease activity (see below). 
Secondly, the severe delay in mounting 
an adaptive immune response (often 
several weeks), despite the presence 
of replicating virus, is probably central 
to the capacity of HCV to set up long-
term persistence, since it has already 
established an important numerical 
advantage [28].
The liver is a site of enrichment for 
memory T cell populations, regardless 
of the virus, as has been shown in 
well-controlled murine models [29]. 
Similarly, enriched populations of 
CD8+ T cells speciﬁc for Epstein-
Barr virus and CMV may be found 
even in normal human liver [30]. 
Chronic HCV infection studies using 
major histocompatibility complex 
class I peptide tetramers (which can 
directly identify antigen-speciﬁc T 
cells, regardless of their function) 
have also shown relatively enriched 
populations in liver biopsies compared 
to blood [31,32]. In some cases, T 
cell populations may fall below the 
level of detection in blood but be 
demonstrated in the liver. However, 
generally such populations are still 
less than 1% to 20% of the total CD8 
inﬁltrate—i.e., the majority of the T 
cell inﬁltrate in the liver in chronic 
HCV is not apparently HCV speciﬁc.
It also appears that the CD8+ T 
cells in the liver may have an unusual 
cytokine secretion proﬁle, with 
some studies linking them with IL-
10 secretion [33,34]. Antiviral CD8+
T cells typically secrete interferon 
(IFN)-gamma, and this has also been 
shown in T cells derived from the liver. 
However, a relative increase in IL-10 
secretion within liver tissue has been 
proposed to limit the tissue damage 
associated with these T cell inﬁltrates, 
and an inverse relationship with 
hepatic inﬂammation has been shown 
[33]. Relatively little is known about 
the quality and quantity of virus-speciﬁc 
CD4+ T cells in the liver, although IL-
10 secretion in this subset has been 
reported [35]. A recent study has 
shown that around 40% of the CD4+
inﬁltrate in HCV-monoinfected livers is 
FOXP3+, regardless of histologic stage 
[36]. This was much higher than the 
ﬁgure in autoimmune liver disease, and 
implies a very large hepatic regulatory 
T cell presence in chronic HCV.
These data indicate overall that 
in chronic HCV infection antiviral 
T cells do home to the infected liver 
and continue to secrete antiviral 
cytokines. However, within the hepatic 
environment, there appears to be a 
regulatory process occurring, which 
likely comprises multiple cell subsets. 
In other words, the T cell inﬁltrate 
in the liver probably contributes to 
three main effects: control of virus 
replication, induction of hepatic 
inﬂammation, and regulation of such 
inﬂammation (Figure 1).
The Main Clinical Effects of HIV 
Infection
HIV coinfection signiﬁcantly affects 
every stage of HCV disease progression 
(Table 1). Firstly, a higher rate of viral 
persistence is seen [2,37]. Secondly, 
and most strikingly, higher viral loads—
about 0.5 to 1 log higher on average 
than in monoinfected individuals—are 
seen in most studies [2,38,39]. This 
high load is associated with higher 
transmission rates, for example in 
mother-to-child transmission studies 
[40]. It may also contribute to the 
recent outbreaks of transmission 
of HCV amongst HIV-positive men 
in European and North American 
cities [41]. The higher loads are also 
associated with a reduced response to 
therapy using standard interferon/
ribavirin combinations [42].
Most important, however, as far 
as patients are concerned is the fact 
that accelerated ﬁbrosis and rates 
of cirrhosis have all been observed, 
leading to increased morbidity and 
mortality associated with HCV for 
HIV-infected individuals [4,43–46]. 
This is an important ﬁnding clinically, 
but also perhaps an unexpected 
one. Many studies of HCV have 
suggested that disease progression 
is not closely linked to virus load, 
unlike in HIV [47]. Interestingly, 
there are some studies which do link 
HCV load and disease progression, 
although such cohorts may also 
include HIV-coinfected subjects 
[47,48]. Other cofactors that may 
accelerate the disease process in 
HIV–HCV coinfection are alcohol use, 
age, gender, and race. Confounding 
this further is the presence of other 
Five Key Studies in the Field
1. Cox et al., 2005 [18] This paper
revealed the extent of immune escape
from CD8+ T cells that occurs after
acute HCV infection.
2. Kim et al., 2005 [56] This paper was
the ﬁrst to look comprehensively at
HCV-speciﬁc CD8+ T cell responses in
coinfected patients, and revealed a
deﬁcit associated with lowered CD4
counts.
3. Accapezzato et al., 2004 [33]
This paper provided evidence for an
unexpected regulatory role of CD8+ T
cells in the liver in HCV.
4. Grakoui et al., 2003 [9] This paper
showed clear evidence for a protective
role of CD4+ T cells against HCV
persistence and reinfection.
5. Thomas et al., 2000 [39] This clinical
study revealed the clear impact of HIV
on control of HCV viral load in chronic
infection.PLoS Medicine  |  www.plosmedicine.org 1611 October 2007  |  Volume 4  |  Issue 10  |  e240
metabolic issues such as steatosis, 
which may be related to antiretroviral 
therapies. Despite all these cofactors, 
HIV-induced immunosuppression 
has an independent effect on ﬁbrosis 
progression [49,50].
How are these effects of HIV 
on HCV infection explained? In 
particular, to what extent do the 
current immunological data help us 
understand the distinct phenomena 
associated with coinfection—most 
notably a rise in viral load and an 
increase in disease progression (Figure 
1)?
Impact of HIV on HCV-Speciﬁc 
Immune Responses
Impact on virus load. While HIV-
mediated effects on the immune system 
are complex, two primary outcomes 
are the decline of CD4+ T lymphocytes, 
resulting in AIDS, and chronic immune 
activation. Shortly following acute HIV 
infection of humans and macaques, a 
massive depletion of mucosal memory 
CD4+ T cells is observed, which is only 
partially reversed by antiretroviral 
therapy [51]. Then with progressive 
infection, a generalized chronic 
immune activation state accompanies 
the gradual decline in immunity to 
various pathogens. Given both of these 
effects, one would predict loss of the 
quantity and function of HCV-speciﬁc 
T cells, particularly CD4+ T cells, in 
coinfected persons.
Studies of peripheral blood 
mononuclear cells indicate that 
HCV-speciﬁc CD4+ T cells are at 
extraordinarily low frequency in 
coinfected subjects, whether measured 
by proliferation or cytokine secretion 
[52–54], including some emerging data 
from acute disease [55]. This loss of 
antiviral CD4 responses has not been 
closely linked to CD4 T cell count, and 
may therefore occur relatively early. 
The observation of loss of HCV-speciﬁc 
CD4+ T cell responses is striking for 
two reasons. Firstly, they are already 
considered relatively weak responses in 
chronic monoinfection, by comparison 
with those with resolved infection, 
or with responses to other persistent 
pathogens [16]. However, it is clear 
that these responses may be further 
impaired and these defects may be 
linked to further loss of control over 
the virus. In other words, the response 
in persistent HCV, while ineffective 
at controlling the virus completely, 
may well be setting an important limit 
on virus load. What is not yet clear, 
however, is why HCV-speciﬁc responses 
should be relatively sensitive to the 
effects of HIV, given that responses to 
other infectious agents only decline 
substantially at later stages of HIV 
progression.
In addition to profound loss of 
virus-speciﬁc CD4+ T cells, there is 
documented failure of CD8+ T cell 
responses. Peripheral total CD4 
counts correlate with the magnitude 
and breadth of the HCV-speciﬁc CD8 
IFN-gamma response [56]. This is in 
stark contrast to the HIV-speciﬁc CD8 
response, which can persist despite 
high HIV viral loads and low CD4 
counts. Interestingly, in a subset of 
those with spontaneous control of 
viremia, an increased rate of viral 
recurrence in coinfected subjects has 
been seen [57–59]. One study was able 
to measure immune responses before 
and after recurrent HCV and found 
that preserved immunity correlated 
with lower viral loads following 
recurrence [57]. This latter observation 
further supports the idea that in 
chronic HCV monoinfection, although 
responses are somewhat limited by 
escape, exhaustion, and regulation, 
they nevertheless make an important 
contribution towards control of 
viremia, including during a secondary 
challenge with HCV, a control which is 
severely disrupted by the action of HIV.
Impact on disease progression. The
consequences of depletion of IFN-
gamma-secreting T cells, as detected in 
the periphery, upon the pathogenesis 
of HCV infection within the liver 
remain unknown. We propose three 
basic models which might explain this 
important link.
1. Impact through increased virus 
load alone. Since HIV depletes HCV-
speciﬁc T cells, and this is accompanied 
by an increase in virus load, the 
simplest model would be—as for other 
pathogens—that the increase in load is 
responsible for the disease progression 
(in this case, inﬂammation/ﬁbrosis). 
The problem with this hypothesis 
is that in monoinfection, the link 
between load and pathology is not very 
strongly supported [47], although it 
has been observed [48]. It is therefore 
possible that the extremely high HCV 
loads seen in HIV–HCV coinfection, 
over very long periods, have additional 
direct and detrimental effects on the 
liver, or indirect effects in combination 
with other mechanisms [60].
2. Loss of regulation. As mentioned 
above, HCV infection is associated 
with the emergence of a number of 
immune regulators, including FOXP3+ 
regulatory T cells and IL-10-secreting 
intrahepatic CD8+ T cells. The anti-
inﬂammatory effects of these may 
contribute to control of liver damage 
in the short term and thus may be 
antiﬁbrotic in the long term. While the 
intrahepatic environment in HCV–HIV 
coinfection has been the subject 
of only limited study, histologically 
there is a profound loss of CD4+T
cells [61]. One study demonstrated a 
depletion of total intrahepatic CD4 T 
cells out of proportion to declines in 
peripheral counts, indicating that the 
inﬂammatory inﬁltrate in the liver is 
missing a key component of an effective 
T cell response. Given that nearly half 
of these cells may be FOXP3+ [36]—
i.e., with likely regulatory function—
this could severely affect both antiviral 
and anti-inﬂammatory function. 
In keeping with this, functional data 
suggest a loss of IL-10-secreting cells 
[35]. The reported HIV-associated 
dysregulation of various cytokines 
[62], including TGF-beta, IL-10, and 
IFN-gamma, secreted by the cellular 
inﬁltrate may tilt the balance towards a 
proﬁbrotic state. The regulation of liver 
ﬁbrosis is complex—although it has 
been classically linked to Th1-mediated 
tissue injury, there is emerging 
evidence that Th2 cell subsets may 
play a proinﬂammatory role, with a 
particularly important role for IL-13-
secreting CD4+ T cells [63]. Much more 
work is required in both mono- and 
coinfection to assess the role of pro- as 
well as anti-inﬂammatory subsets in this 
organ.
3. Indirect effects. While we have 
focused here on the speciﬁc T cell–
mediated antiviral responses, HIV and 
HCV both have effects on other cell 
subsets, including NK cells [64,65] , 
NKT cells [65,66], gamma delta cells 
[60,66], and potentially on cytokine-
secreting antigen-presenting cells in the 
liver [67]. It remains possible that the 
impact of HIV on disease pathogenesis 
occurs through modulation of such 
cells. B cell responses to HCV are also 
diminished in the presence of HIV 
[68]. Although all these theories are 
possible, it will be extremely difﬁcult 
to disentangle the role of any one of PLoS Medicine  |  www.plosmedicine.org 1612 October 2007  |  Volume 4  |  Issue 10  |  e240
them on disease progression due to 
the multitude of potentially interacting 
cell subsets, independent from the 
profound effects described above.
Treatment Considerations
HCV therapy. The adverse impact of 
HIV on treatment outcome for HCV 
has been well documented. While there 
have been advances, even with the best 
of treatments we do not successfully 
treat HCV infection in the majority 
of those with coexisting HIV [69]. 
What explanations do studies of HCV 
immunopathogenesis offer us?
The simplest model is that virus 
clearance induced by interferon-
based therapy is closely linked to 
pretreatment virus load [42]. Thus 
failure of the immune response to 
contain virus in the steady state could 
alone account for a failure of antiviral 
therapy in the long term. There has, 
however, been much interest in the 
role of immune responses in long-
term treatment outcome. One reason 
for this is that both interferon and 
ribavirin have immunomodulatory 
roles, and thus it seems plausible 
that these could contribute to the 
treatment effect—especially since the 
direct antiviral effect of ribavirin is 
minimal. However, the evidence that 
T cells play a major role in treatment 
outcome is still fairly weak. Some 
studies have linked a boosting of T 
cell responses to sustained virologic 
responses [70], but others have found 
only limited evidence [71]. Treatment 
in acute disease, where therapy is 
most successful and T cells are at 
their highest frequency, is associated 
with, if anything, a reduction in T cell 
responses [72,73]. One plausible model 
is that T cell responses contribute to 
the long-term treatment outcome, but 
it is the pre-existing responses, rather 
than treatment-boosted responses, 
which are important. Under this 
model, if T cells and interferon are 
synergistic, then the markedly reduced 
T cell response to HCV in coinfection 
could still have a role to play in the 
poor treatment response.
HIV therapy. Emerging evidence 
suggests that long-term highly active 
ART does lead to a reduction in 
HCV-related liver disease [4,43–46]. 
Disease progression, which is affected 
by a number of other factors in such 
cohorts—including alcohol—is linked 
to low CD4+ T cell count, and reversal 
of this defect seems sufﬁcient to reduce 
the rates of progression signiﬁcantly.
What is not known is to what extent 
the treatment of HIV with effective 
ART can restore the T cell responses 
to HCV in the long term. Indeed, the 
clinical effect of ART on HCV load has 
been quite controversial, with small 
studies suggesting a range of different 
outcomes [74–77]. Certainly it does 
not appear a simple relationship 
whereby a drop in HCV load follows 
from a drop in HIV load, although this 
may occur rarely [78]. Restoration of 
CD4+ T cell responses against many 
other pathogens and antigens has 
been observed after ART, so might be 
expected in HCV. However, generally 
T cell responses against persistent 
pathogens such as CMV and Epstein-
Barr virus are much stronger prior to 
immunosuppression than those against 
HCV [16]. If disease progression is 
slowed, without substantial increases in 
antiviral responses against HCV (linked 
to decreasing viral loads), this would 
support the idea that what is being 
repaired is not speciﬁc control over 
this tricky pathogen, but rather the 
immune dysregulation related to HIV 
replication. Further careful prospective 
studies are needed to address this 
critical point.
Conclusions: Future Steps
The major impact of HIV on HCV 
infection has become clear in the 
last few years from careful large-scale 
clinical studies (Box 1). While a 
negative impact is to be expected from 
HIV coinfection, by comparison with 
other pathogens, the magnitude of the 
effect is actually striking. 
Emerging evidence suggests that the 
major impact on virus load may well 
be explained by the observed changes 
in HCV-speciﬁc CD4+ and CD8+ T cell 
responses, particularly the striking 
changes in the former. However, this 
observation has shed important light 
on the substantial impact of these 
responses on the control of HCV 
in monoinfection, a feature which 
was perhaps underappreciated. The 
impact on disease progression may 
be inﬂuenced by high viral load, 
but it is very likely that defects in 
other regulatory populations play a 
role. In a similar way, deﬁning these 
populations in more detail will give 
important clues into what controls the 
rate of progression in monoinfection. 
However, much more work needs to be 
done in this area.
Most importantly, the capacity 
to recover immunologically from 
this position is not yet established. 
There are numerous complex clinical 
considerations to take into account in 
deciding whom to treat and when, how 
and in what order, which are reviewed 
elsewhere [79]. The bottom line appears 
to be that effective therapy for HIV, 
in those with signiﬁcant CD4 loss, has 
important additional beneﬁts for HCV 
disease, even if HCV persists. Whether 
this effect occurs through restoration 
of HCV-speciﬁc immune responses 
or recovery of regulatory cell subsets 
or some other unrelated mechanism 
remains to be determined. Given their 
overall signiﬁcance, at least deﬁning 
the quality of immune responses and 
relating this to clinical parameters after 
the initiation of ART for HIV seems an 
important and practical goal.
HIV–HCV coinfection has 
created a signiﬁcant clinical burden. 
Nonetheless, through the clinical 
insights gained it has provided some 
unique opportunities to understand the 
control of HCV and its pathogenesis. 
Hopefully in the future the growing 
scale of the problem will be matched 
by additional clinical–immunological 
studies to disentangle this further and 
potentially—in the longer term—
provide further avenues for deﬁning 
prognosis and improving treatment.  
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